These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12762290)

  • 1. New concept in the pathogenesis of cardiovascular disease.
    Albu JB; Rozanski A; Epstein SE
    AIDS Read; 2003 Apr; 13(4 Suppl):S20-4. PubMed ID: 12762290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Increased cardiovascular risk in HIV patients].
    Wierema TK
    Ned Tijdschr Geneeskd; 2010; 154():A788. PubMed ID: 20456808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006).
    Carosi G; Quiros-Roldan E; Torti C; Antinori A; Bevilacqua M; Bonadonna RC; Bonfanti P; Castagna A; Cauda R; d'Arminio-Monforte A; Di Gregorio P; Di Perri G; Esposito R; Fatuzzo F; Gervasoni C; Giannattasio C; Guaraldi G; Lazzarin A; Lo Caputo S; Maggi P; Mazzotta F; Moroni M; Prestileo T; Ranieri R; Rizzardini G; Russo R; Galli M;
    Infection; 2007 Jun; 35(3):134-42. PubMed ID: 17565453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk.
    Barbaro G
    Am J Ther; 2006; 13(3):248-60. PubMed ID: 16772767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular disease and toxicities related to HIV infection and its therapies.
    Zareba KM; Miller TL; Lipshultz SE
    Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment.
    Crook M
    Ann Clin Biochem; 2007 May; 44(Pt 3):219-31. PubMed ID: 17456292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.
    Magen E; Elbirt D; Sthoeger Z
    Isr Med Assoc J; 2005 Apr; 7(4):252-6. PubMed ID: 15847207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
    Grover SA; Coupal L; Gilmore N; Mukherjee J
    Am J Cardiol; 2005 Mar; 95(5):586-91. PubMed ID: 15721096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyslipidaemia and cardiovascular risk in HIV infection.
    Kulasekaram R; Peters BS; Wierzbicki AS
    Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
    Leclercq P; Blanc M
    Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors.
    Boccara F
    AIDS; 2008 Sep; 22 Suppl 3():S19-26. PubMed ID: 18845918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin Resistance and the cardiometabolic syndrome in HIV infection.
    Bevilacqua M; Dominguez LJ; Barbagallo M
    J Cardiometab Syndr; 2009; 4(1):40-3. PubMed ID: 19245515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
    Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
    Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of cardiovascular disease in patients receiving antiretroviral therapy for HIV infection: implications for treatment.
    Steinhart CR; Emons MF
    AIDS Read; 2004 Feb; 14(2):86-90, 93-5. PubMed ID: 14997864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
    Calza L; Manfredi R; Chiodo F
    J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular disease in patients infected with the human immunodeficiency virus.
    Velasquez EM; Glancy DL
    J La State Med Soc; 2003; 155(6):314-24. PubMed ID: 14750751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HIV infection: emerging issues and new challenges].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2006 Dec; 97(12):771-80. PubMed ID: 17252736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.